 Response rates survival primary systemic amyloidosis Patients biopsy-proven primary systemic amyloidosis AL response rate agent-based chemotherapy patients serum creatinine concentration adverse effect response rate patients nephrotic syndrome normal serum creatinine value echocardiographic evidence cardiac amyloidosis response rate patients amyloid cardiomyopathy alive years diagnosis None patients amyloid peripheral neuropathy regression disease median time response months median survival patients months years patients alive minimum follow-up months Seven acute leukemia dysmyelopoietic syndrome presumed complication melphalan therapy group patients response agent-based therapy median survival months years patients agent-based chemotherapy AL beneficial subset patients trial chemotherapy patients survival benefit